MediWound Ltd. is an Israel-based biopharmaceutical company, headquartered in Yavne, that develops next-generation enzymatic, non-surgical therapies for tissue repair. Its FDA-approved biologic, NexoBrid, is indicated for the enzymatic removal of eschar in severe thermal burns and is marketed in the United States by partner Vericel (VCEL), as well as in the European Union, Japan, and additional international markets. The company's lead pipeline candidate, EscharEx, is an investigational therapy for the debridement of chronic wounds such as venous leg ulcers, a substantially larger market than burn care. MediWound's revenue combines product sales and development services tied to U.S. government programs, including contracts with the Biomedical Advanced Research and Development Authority (BARDA) and the Department of War. I checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors follow the stock for its established commercial franchise, government partnerships, and a late-stage pipeline asset with a pivotal readout on the horizon.
Over the last 30 days, MDWD rose from a closing price of $12.10 on October 21, 2026, to approximately $13.49, a gain of about 11.5%. The move reflects a recovery from a mid-October low near $11.85, followed by renewed buying into and after the company's November 12 quarterly report. On a quarterly basis, the stock has been comparatively subdued: from roughly $13.12 in late August to about $13.49, the shares are up a modest 2.9% over three months. In effect, the last quarter has been characterized by a pullback through late September and October, followed by a sharp rebound that has returned the stock to its late-summer range.
The 30-day advance was anchored by the company's third-quarter 2026 report, released November 12. While revenue of $3.6 million missed consensus and management acknowledged that its 2026 outlook now depends on uncertain U.S. government funding discussions, the update emphasized tangible commercial and clinical progress. Partner Vericel reported NexoBrid's strongest quarter since launch, with record revenue, ordering burn centers, and hospital orders, while BARDA procurement began during the period. Management also confirmed the EscharEx Phase III VALUE trial remains on track, with an independent data and safety monitoring board flagging no safety concerns. Separately, the U.S. Department of War awarded an additional $3.3 million in non-dilutive funding for a room-temperature-stable NexoBrid formulation, and the company closed a $17.25 million public offering that strengthened its balance sheet. Broadly constructive analyst coverage, including a Buy rating with a $36 price target, reinforced sentiment, helping the stock recover after a brief post-earnings dip. From what I see, this combination of commercial traction and non-dilutive capital provided a solid foundation for the rebound.
The broader three-month trend has been shaped by execution across two fronts: commercializing NexoBrid and advancing EscharEx toward a pivotal data readout. Enrollment continued in the global VALUE trial across roughly 40 sites, with management reaffirming guidance for interim assessment and enrollment completion by the end of the first quarter of 2027. On the manufacturing side, the company completed routine GMP inspections at its operating NexoBrid facility and progressed work on an expanded facility, though commercial supply from that expansion is not expected until the second half of 2027. Offsetting these positives, revenue declined year over year because of lower government development-services revenue, and demand for NexoBrid continued to outpace available manufacturing capacity. These cross-currents kept the shares range-bound for much of the quarter until the November catalysts sparked the latest leg higher.
Looking ahead, the principal catalyst for MediWound is the EscharEx Phase III VALUE trial, with enrollment completion and interim sample-size reassessment targeted for the end of the first quarter of 2027 and top-line data expected around mid-2027. Investors will also monitor NexoBrid's U.S. uptake, continued BARDA procurement, and progress on the expanded manufacturing facility, which remains subject to regulatory approval. Financial items to watch include the outcome of ongoing U.S. government funding discussions for a planned U.S.-based facility, cash burn, and any additional capital-raising activity. Macroeconomic factors, sector sentiment toward clinical-stage biotechs, and regulatory developments in wound care reimbursement may also influence the shares. I'm watching this closely as the trial timelines approach.
I often review Tickeron’s Trending AI Robots to see which automated strategies are gaining traction on names like this. The platform curates top-performing bots across different timeframes and approaches, letting me compare options that align with my own risk parameters before deciding whether to follow any particular model. This gives a practical way to explore AI-driven ideas without sifting through hundreds of strategies.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Stochastic Oscillator for MDWD moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 52 similar instances where the indicator exited the overbought zone. In 45 of the 52 cases the stock moved lower. This puts the odds of a downward move at 87%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDWD as a result. In 74 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for MDWD turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 35 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDWD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
MDWD broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MDWD entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MDWD's RSI Oscillator exited the oversold zone, 27 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
MDWD moved above its 50-day moving average on November 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MDWD crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Following a +6.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDWD advanced for three days, in 184 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.161) is normal, around the industry mean (3.596). P/E Ratio (-8.906) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (14.045) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. MDWD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDWD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biopharmaceutical company
Industry Biotechnology